PEPTIDEDOSAGE

VK2735 Dosage Chart

Medically reviewed June 21, 2026 · Page updated November 21, 2026

TYPICAL RESEARCH DOSE

2.5-15 mg once weekly (subcutaneous, titrated)

30 mg vial + 1.5 mL bacteriostatic water

20 mg/mL · 1 unit = 200 mcg on a U-100 syringe

PHASE	DOSE PER INJECTION	UNITS (PER INJECTION)
Weeks 1-4 — initiation (start low)	2500 mcg (2.5 mg)	13 units (0.13 mL)
Weeks 5-8 — first escalation	5000 mcg (5 mg)	25 units (0.25 mL)
Weeks 9-12 — second escalation	10000 mcg (10 mg)	50 units (0.50 mL)
Week 13+ — top dose studied in VENTURE	15000 mcg (15 mg)	75 units (0.75 mL)

VK2735 dose to syringe units, by vial size

U-100 insulin syringe: 100 units = 1 mL.

DOSE	30 MG VIAL + 1.5 ML (20 MG/ML)
2.5 mg	12.5 units (0.125 mL)
5 mg	25 units (0.25 mL)
10 mg	50 units (0.5 mL)
15 mg	75 units (0.75 mL)

STORAGE

Lyophilized powder stored frozen at -20 °C and protected from light; reconstituted solution refrigerated at 2-8 °C and used within approximately 4 weeks. Avoid freezing the reconstituted liquid and do not expose to heat or direct sunlight.

Educational reference only, not medical advice. Figures restate the research protocol published at the address above.